Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Leishen Energy Holding Co., Ltd. - Ordinary Shares (NQ: LSE )

7.560 -0.060 (-0.79%)
Streaming Delayed Price Updated: 3:59 PM EST, Feb 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,675
Open 8.050
Bid (Size) 7.210 (1)
Ask (Size) 8.400 (4)
Prev. Close 7.620
Today's Range 7.560 - 8.349
52wk Range 3.760 - 13.83
Shares Outstanding 75,936,172
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Nexxen Fuels Growth with Live Sports Offerings and Key Partnerships, Reaching Highly Engaged Audiences Across Channels
By collaborating with publisher partners and DSPs, Nexxen saw an increase in spend on live sports packages, including a 315% increase from StackAdapt campaigns 
From Nexxen International Ltd.
Via GlobeNewswire

Performance

YTD
+46.23%
+46.23%
1 Month
+37.70%
+37.70%
3 Month
+73.79%
+73.79%
6 Month
+73.79%
+73.79%
1 Year
+73.79%
+73.79%

More News

Read More
Caledonia Mining Corporation Plc: Blanket Mine Q4 and FY 2024 Production and 2025 Guidance
From Caledonia Mining Corporation Plc
Via GlobeNewswire
HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
From HUTCHMED (China) Limited
Via GlobeNewswire
HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Nexxen Launches Nexxen U, a First-of-its-Kind Education Program for Linear, Connected TV and Digital Convergence
From Nexxen International Ltd.
Via GlobeNewswire
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture
From HUTCHMED (China) Limited
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.